Aug 8, 2019 4:05 pm EDT Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update
Jul 30, 2019 5:30 am EDT Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
Jul 23, 2019 5:30 am EDT Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
Jun 21, 2019 5:30 am EDT Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Jun 11, 2019 7:00 am EDT Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
May 30, 2019 5:30 am EDT Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
May 15, 2019 4:05 pm EDT Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
May 7, 2019 5:30 am EDT Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
Apr 24, 2019 5:30 am EDT Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
